Marvel Biosciences（MBCO.F）株式概要バイオテクノロジー企業であるマーベル・バイオサイエンシズ社は、カナダで新疾患の適応症として承認された先発薬の合成化学誘導体を開発している。 詳細MBCO.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析意味のある時価総額がありません ( $7M )マイナスの株主資本 収益が 100 万ドル未満 ( CA$0 )US市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見るMBCO.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.11該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesMarvel Biosciences Corp. 競合他社Acurx PharmaceuticalsSymbol: NasdaqCM:ACXPMarket cap: US$7.1mXenetic BiosciencesSymbol: NasdaqCM:XBIOMarket cap: US$6.7mSynlogicSymbol: OTCPK:SYBXMarket cap: US$7.7mAlpha ComputeSymbol: NasdaqCM:ALPMarket cap: US$9.0m価格と性能株価の高値、安値、推移の概要Marvel Biosciences過去の株価現在の株価CA$0.1152週高値CA$0.2452週安値CA$0.058ベータ0.621ヶ月の変化8.30%3ヶ月変化1.04%1年変化110.26%3年間の変化n/a5年間の変化n/aIPOからの変化56.31%最新ニュースお知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offeringお知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.最新情報をもっと見るRecent updatesお知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offeringお知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.お知らせ • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.お知らせ • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.お知らせ • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.お知らせ • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.お知らせ • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.お知らせ • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.株主還元MBCO.FUS BiotechsUS 市場7D-6.9%1.2%1.0%1Y110.3%34.9%28.7%株主還元を見る業界別リターン: MBCO.F過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: MBCO.F過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is MBCO.F's price volatile compared to industry and market?MBCO.F volatilityMBCO.F Average Weekly Movement18.9%Biotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: MBCO.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: MBCO.Fの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aRod Mathesonmarvelbiotechnology.comバイオテクノロジー企業であるマーベル・バイオサイエンシズ社は、カナダで新疾患の適応症として承認された先発薬の合成化学誘導体を開発している。同社のリード化合物であるMB-204は、アデノシンA2a受容体拮抗薬であるイストラデフィリンの新規フッ素化誘導体で、アルツハイマー病や自閉症スペクトラム障害のほか、うつ病や不安神経症、ADHD、癌の非神経症状、非アルコール性脂肪性肝炎の治療に使用される。また、非幻覚性神経可塑性プログラムを提供している。本社はカナダのカルガリー。もっと見るMarvel Biosciences Corp. 基礎のまとめMarvel Biosciences の収益と売上を時価総額と比較するとどうか。MBCO.F 基礎統計学時価総額US$7.30m収益（TTM）-US$1.51m売上高(TTM)n/a0.0xP/Sレシオ-4.8xPER（株価収益率MBCO.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MBCO.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$2.09m収益-CA$2.09m直近の収益報告Jan 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.033グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-59.9%MBCO.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 23:36終値2026/05/21 00:00収益2026/01/31年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Marvel Biosciences Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.
お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.
お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.
お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.
お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering
お知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.
お知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.
お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.
お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.
お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.
お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering
お知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.
お知らせ • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.
お知らせ • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.
お知らせ • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.
お知らせ • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.
お知らせ • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.
お知らせ • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.
